Your institution may have access to this item. Find your institution then sign in to continue.
Title
Retracing events.
Abstract
The author reflects on the link between adeno-associated virus (AAV) gene therapy and the patient's death treated with it in the U.S. He denotes that the two deaths in seven years connected to gene therapy should not be the reason for a regulatory crackdown. He asserts that further research on the AAV platform should be encouraged for clinical trials.